Published in Autoimmun Rev on May 12, 2014
New Immunosuppressive Therapies in Uveitis Treatment. Int J Mol Sci (2015) 0.77
Risk factors of uveitis in ankylosing spondylitis: An observational study. Medicine (Baltimore) (2016) 0.75
Transient antibody targeting of CD45RC induces transplant tolerance and potent antigen-specific regulatory T cells. JCI Insight (2017) 0.75
Novel CD28 antagonist mPEG PV1-Fab' mitigates experimental autoimmune uveitis by suppressing CD4+ T lymphocyte activation and IFN-γ production. PLoS One (2017) 0.75
The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer (2012) 24.94
Immunologic self-tolerance maintained by CD25(+)CD4(+) regulatory T cells constitutively expressing cytotoxic T lymphocyte-associated antigen 4. J Exp Med (2000) 13.13
Monoclonal antibodies defining distinctive human T cell surface antigens. Science (1979) 10.50
TH17 cells contribute to uveitis and scleritis and are expanded by IL-2 and inhibited by IL-27/STAT1. Nat Med (2007) 5.41
TAM receptors are pleiotropic inhibitors of the innate immune response. Cell (2007) 5.32
Either a Th17 or a Th1 effector response can drive autoimmunity: conditions of disease induction affect dominant effector category. J Exp Med (2008) 5.25
Complexities of CD28/B7: CTLA-4 costimulatory pathways in autoimmunity and transplantation. Annu Rev Immunol (2001) 4.99
Treatment of rheumatoid arthritis by selective inhibition of T-cell activation with fusion protein CTLA4Ig. N Engl J Med (2003) 4.67
Homeostatic regulation of the immune system by receptor tyrosine kinases of the Tyro 3 family. Science (2001) 4.42
Incidence and prevalence of uveitis in Northern California; the Northern California Epidemiology of Uveitis Study. Ophthalmology (2004) 4.06
Rational development of LEA29Y (belatacept), a high-affinity variant of CTLA4-Ig with potent immunosuppressive properties. Am J Transplant (2005) 4.05
Anti-CD3 antibody induces long-term remission of overt autoimmunity in nonobese diabetic mice. Proc Natl Acad Sci U S A (1994) 3.77
Durable cancer regression off-treatment and effective reinduction therapy with an anti-PD-1 antibody. Clin Cancer Res (2012) 3.68
Identification and distribution of the costimulatory receptor CD28 in the mouse. J Immunol (1992) 3.37
Spontaneous autoimmunity prevented by thymic expression of a single self-antigen. J Exp Med (2006) 3.20
Oral CD3-specific antibody suppresses autoimmune encephalomyelitis by inducing CD4+ CD25- LAP+ T cells. Nat Med (2006) 2.93
Endotoxin-induced uveitis in rats as a model for human disease. Nature (1980) 2.85
A new model of autoimmune disease. Experimental autoimmune uveoretinitis induced in mice with two different retinal antigens. J Immunol (1988) 2.68
Experimental allergic uveitis. Isolation, characterization, and localization of a soluble uveitopathogenic antigen from bovine retina. J Immunol (1977) 2.48
Costimulatory blockade in patients with rheumatoid arthritis: a pilot, dose-finding, double-blind, placebo-controlled clinical trial evaluating CTLA-4Ig and LEA29Y eighty-five days after the first infusion. Arthritis Rheum (2002) 2.44
A look at autoimmunity and inflammation in the eye. J Clin Invest (2010) 2.30
A randomized, placebo-controlled, double-masked clinical trial of etanercept for the treatment of uveitis associated with juvenile idiopathic arthritis. Arthritis Rheum (2005) 2.20
Treatment of noninfectious intermediate and posterior uveitis with the humanized anti-Tac mAb: a phase I/II clinical trial. Proc Natl Acad Sci U S A (1999) 2.14
"Cytokine storm" in the phase I trial of monoclonal antibody TGN1412: better understanding the causes to improve preclinical testing of immunotherapeutics. J Immunol (2007) 2.11
Uveitis and systemic disease. Br J Ophthalmol (1992) 1.88
CD28/B7 costimulation: a review. Crit Rev Immunol (1998) 1.87
Differential efficacy of tumor necrosis factor inhibition in the management of inflammatory eye disease and associated rheumatic disease. Arthritis Rheum (2001) 1.85
Interleukin-2 in the development and control of inflammatory disease. Immunol Rev (2008) 1.83
CTLA-4 regulates cell cycle progression during a primary immune response. Eur J Immunol (2002) 1.78
CTLA4Ig: bridging the basic immunology with clinical application. Immunity (2006) 1.75
Prevention of autoimmune diabetes with nonactivating anti-CD3 monoclonal antibody. Diabetes (1992) 1.74
The costimulatory molecule ICOS plays an important role in the immunopathogenesis of EAE. Nat Immunol (2001) 1.74
Abatacept for severe anti-tumor necrosis factor alpha refractory juvenile idiopathic arthritis-related uveitis. Arthritis Care Res (Hoboken) (2010) 1.70
CD3-specific antibody-induced active tolerance: from bench to bedside. Nat Rev Immunol (2003) 1.70
From IL-2 to IL-37: the expanding spectrum of anti-inflammatory cytokines. Nat Immunol (2012) 1.70
IFN-gamma-deficient mice develop experimental autoimmune uveitis in the context of a deviant effector response. J Immunol (1997) 1.68
Humanized anti-interleukin-2 (IL-2) receptor alpha therapy: long-term results in uveitis patients and preliminary safety and activity data for establishing parameters for subcutaneous administration. J Autoimmun (2003) 1.66
Corneal antigen-presenting cells. Chem Immunol Allergy (2007) 1.53
The role of FasL-induced apoptosis in immune privilege. Immunol Today (1997) 1.39
Pivotal role of the B7:CD28 pathway in transplantation tolerance and tumor immunity. Blood (1994) 1.38
B7RP-1 blockade ameliorates autoimmunity through regulation of follicular helper T cells. J Immunol (2009) 1.38
Spontaneous retinopathy in HLA-A29 transgenic mice. Proc Natl Acad Sci U S A (2001) 1.38
Ocular autoimmunity: the price of privilege? Immunol Rev (2006) 1.35
Vogt-Koyanagi-Harada syndrome. Autoimmun Rev (2013) 1.35
Cellular immune responses of patients with uveitis to retinal antigens and their fragments. Am J Ophthalmol (1990) 1.35
A humanized model of experimental autoimmune uveitis in HLA class II transgenic mice. J Clin Invest (2003) 1.32
Genetic susceptibility to experimental autoimmune uveitis involves more than a predisposition to generate a T helper-1-like or a T helper-2-like response. J Immunol (1997) 1.31
Diagnosis and classification of Vogt-Koyanagi-Harada disease. Autoimmun Rev (2014) 1.29
Manipulation of regulatory T-cell number and function with CD28-specific monoclonal antibodies. Adv Immunol (2007) 1.29
Modified anti-CD3 therapy in psoriatic arthritis: a phase I/II clinical trial. J Rheumatol (2002) 1.28
Uveoretinitis and pinealitis induced by immunization with interphotoreceptor retinoid-binding protein. Invest Ophthalmol Vis Sci (1986) 1.27
Humanized antibodies against the alpha-chain of the IL-2 receptor and against the beta-chain shared by the IL-2 and IL-15 receptors in a monkey uveitis model of autoimmune diseases. J Immunol (1997) 1.25
Benign mucous membrane pemphigoid. Arch Dermatol (1971) 1.24
Dendritic cell physiology and function in the eye. Immunol Rev (2010) 1.24
Biologic therapy for autoimmune diseases: an update. BMC Med (2013) 1.23
Establishment and characterization of a murine CD4+ T cell line and clone that induce experimental autoimmune uveoretinitis in B10.A mice. J Immunol (1996) 1.22
Inducing CTLA-4-dependent immune regulation by selective CD28 blockade promotes regulatory T cells in organ transplantation. Sci Transl Med (2010) 1.17
B7-h2 is a costimulatory ligand for CD28 in human. Immunity (2011) 1.17
Efficacy of etanercept in preventing relapse of uveitis controlled by methotrexate. Arch Ophthalmol (2003) 1.16
Immunosuppressive properties of the pigmented epithelial cells and the subretinal space. Chem Immunol Allergy (2007) 1.16
B7-H1 restricts neuroantigen-specific T cell responses and confines inflammatory CNS damage: implications for the lesion pathogenesis of multiple sclerosis. Eur J Immunol (2008) 1.11
Immune checkpoint blockade immunotherapy to activate anti-tumour T-cell immunity. Br J Haematol (2013) 1.09
Breakdown of immune privilege and spontaneous autoimmunity in mice expressing a transgenic T cell receptor specific for a retinal autoantigen. J Autoimmun (2013) 1.07
Experimental autoimmune anterior uveitis. Induction with melanin-associated antigen from the iris and ciliary body. Invest Ophthalmol Vis Sci (1995) 1.06
Retinal pigment epithelium-derived CTLA-2alpha induces TGFbeta-producing T regulatory cells. J Immunol (2008) 1.03
Functional expression of B7H1 on retinal pigment epithelial cells. Exp Eye Res (2007) 1.02
High-dose humanized anti-IL-2 receptor alpha antibody (daclizumab) for the treatment of active, non-infectious uveitis. J Autoimmun (2008) 1.01
The calm after the cytokine storm: lessons from the TGN1412 trial. J Clin Invest (2008) 1.01
Immunohistochemical analysis of experimental autoimmune uveoretinitis (EAU) induced by interphotoreceptor retinoid-binding protein (IRBP) in the rat. Immunol Invest (1987) 0.99
Immune privilege or privileged immunity? Mucosal Immunol (2008) 0.96
Preclinical efficacy and immunological safety of FR104, an antagonist anti-CD28 monovalent Fab' antibody. Am J Transplant (2012) 0.96
Immunogenetic aspects of clinical and experimental uveitis. Reg Immunol (1993) 0.96
Treatment of ocular inflammatory disorders with daclizumab. Ophthalmology (2003) 0.96
Diagnosis and classification of autoimmune uveitis. Autoimmun Rev (2014) 0.93
Effects of experimental ocular inflammation on ocular immune privilege. Invest Ophthalmol Vis Sci (1999) 0.93
Current state of type 1 diabetes immunotherapy: incremental advances, huge leaps, or more of the same? Clin Dev Immunol (2011) 0.92
Comparative analysis of induced vs. spontaneous models of autoimmune uveitis targeting the interphotoreceptor retinoid binding protein. PLoS One (2013) 0.91
Abatacept: a potential therapy in refractory cases of juvenile idiopathic arthritis-associated uveitis. Graefes Arch Clin Exp Ophthalmol (2010) 0.90
CTLA-4 and autoimmunity: new insights into the dual regulator of tolerance. Autoimmun Rev (2013) 0.90
Ocular immune privilege. F1000 Biol Rep (2010) 0.89
A more selective costimulatory blockade of the CD28-B7 pathway. Transpl Int (2010) 0.89
Selective immunosuppression of activated T cells with the chimeric toxin IL-2-PE40. Inhibition of experimental autoimmune uveoretinitis. J Immunol (1989) 0.88
Ocular transfer of retinal glial cells transduced ex vivo with adenovirus expressing viral IL-10 or CTLA4-Ig inhibits experimental autoimmune uveoretinitis. Gene Ther (2003) 0.88
Sarcoidosis and uveitis. Autoimmun Rev (2014) 0.87
Biotherapies in inflammatory ocular disorders: Interferons, immunoglobulins, monoclonal antibodies. Autoimmun Rev (2013) 0.87
Immunologic mechanisms of uveitis. New targets for immunomodulation. Arch Ophthalmol (1997) 0.87
The role of the ICOS/B7RP-1 T cell costimulatory pathway in murine experimental autoimmune uveoretinitis. Eur J Immunol (2006) 0.87
CD28-specific immunomodulating antibodies: what can be learned from experimental models? Am J Transplant (2012) 0.87
B7+ iris pigment epithelial cells convert T cells into CTLA-4+, B7-expressing CD8+ regulatory T cells. Invest Ophthalmol Vis Sci (2006) 0.86
Participation of pigment epithelium of iris and ciliary body in ocular immune privilege. 2. Generation of TGF-beta-producing regulatory T cells. Invest Ophthalmol Vis Sci (2000) 0.85
Blockade of costimulation through B7/CD28 inhibits experimental autoimmune uveoretinitis, but does not induce long-term tolerance. J Immunol (2000) 0.85
The human leukocyte antigen complex and chronic ocular inflammatory disorders. Am J Ophthalmol (2000) 0.85
What causes relapses of autoimmune diseases? The etiological role of autoreactive T cells. Autoimmun Rev (2013) 0.84
TAM receptor knockout mice are susceptible to retinal autoimmune induction. Invest Ophthalmol Vis Sci (2011) 0.84
Experimental autoimmune anterior uveitis (EAAU). II. Dose-dependent induction and adoptive transfer using a melanin-bound antigen of the retinal pigment epithelium. Exp Eye Res (1992) 0.83
Costimulation of memory T-cells by ICOS: a potential therapeutic target for autoimmunity? Clin Immunol (2001) 0.83
Immunological tolerance. Nature (1961) 0.83